COVID-19 IgG, Qualitative by CMIA (COVAB)

INTERMOUNTAIN LABORATORY SERVICES is now offering a qualitative chemistry Chemiluminescent Microparticle Immunoassay (CMIA). The test is intended for the qualitative detection of IgG antibodies to SARS-CoV-2. This assay is only for in vitro diagnostic use under the FDA Emergency Use Authorization.

This test is orderable as of Wednesday, May 6th, 2020.

ORDERING INFORMATION:	**COVAB test code**
SPECIMEN COLLECTION:	Serum Separator Tube (SST), red-top serum, or EDTA plasma
TRANSPORT:	Refrigerated
SAMPLE VOLUME:	0.5 mL of serum or plasma Pediatric minimum of 0.25 mL
STABILITY:	Ambient: 2 days Refrigerated: 7 days Frozen: 7> days
UNNACCEPTABLE:	Heparin, Gray Potassium Oxalate/Sodium Fluoride
PERFORMED/REPORTED:	Daily / 1 – 5 days.

Key Points

- A COVID-19 IgG Serology Patient History Form must accompany the order.
- Negative results do not rule out SARS-CoV-2 infection.
- Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains such as HKU1, NL63, OC43 or 229E.
- Test targets IgG antibodies to the nucleocapsid protein of SARS-CoV-2.
- Results:

Results
Negative
Positive

- Volume: 0.5 mL of serum or plasma.
  Pediatric min. 0.25 mL.

Intermountain® Healthcare